Rhumbline Advisers Crinetics Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 108,719 shares of CRNX stock, worth $5.86 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

108,719

Previous 112,319 3.21%

Holding current value

$5.86 Million

Previous $5.03 Million 10.4%

% of portfolio

0.01%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$43.83 - $54.98 $157,788 - $197,928	-3,600 Reduced 3.21%	108,719 $5.55 Million
Q2 2024 Aug 01, 2024	BUY	$42.12 - $51.91 $152,727 - $188,225	3,626 Added 3.34%	112,319 $5.03 Million
Q1 2024 May 09, 2024	BUY	$34.76 - $46.81 $51,375 - $69,185	1,478 Added 1.38%	108,693 $5.09 Million
Q4 2023 Feb 08, 2024	BUY	$25.62 - $37.07 $16,934 - $24,503	661 Added 0.62%	107,215 $3.81 Million
Q3 2023 Nov 09, 2023	BUY	$15.97 - $30.59 $261,908 - $501,676	16,400 Added 18.19%	106,554 $3.17 Million
Q2 2023 Aug 08, 2023	BUY	$15.73 - $23.6 $129,772 - $194,700	8,250 Added 10.07%	90,154 $1.62 Million
Q1 2023 May 11, 2023	BUY	$15.31 - $21.1 $44,643 - $61,527	2,916 Added 3.69%	81,904 $1.32 Million
Q4 2022 Feb 14, 2023	SELL	$15.49 - $19.05 $108 - $133	-7 Reduced 0.01%	78,988 $1.45 Million
Q3 2022 Nov 10, 2022	BUY	$18.11 - $22.37 $98,500 - $121,670	5,439 Added 7.39%	78,995 $1.55 Million
Q2 2022 Aug 11, 2022	BUY	$16.49 - $27.64 $426,348 - $714,632	25,855 Added 54.2%	73,556 $1.37 Million
Q1 2022 May 12, 2022	BUY	$17.15 - $28.31 $79,816 - $131,754	4,654 Added 10.81%	47,701 $1.05 Million
Q4 2021 Feb 10, 2022	BUY	$19.35 - $28.41 $147,911 - $217,166	7,644 Added 21.59%	43,047 $1.22 Million
Q3 2021 Nov 12, 2021	BUY	$16.88 - $25.23 $31,261 - $46,725	1,852 Added 5.52%	35,403 $745,000
Q2 2021 Aug 05, 2021	BUY	$15.9 - $21.15 $81,948 - $109,007	5,154 Added 18.15%	33,551 $632,000
Q1 2021 May 06, 2021	SELL	$13.3 - $17.55 $31,521 - $41,593	-2,370 Reduced 7.7%	28,397 $434,000
Q4 2020 Feb 10, 2021	BUY	$12.08 - $17.46 $33,582 - $48,538	2,780 Added 9.93%	30,767 $434,000
Q3 2020 Nov 12, 2020	SELL	$13.62 - $17.66 $63,605 - $82,472	-4,670 Reduced 14.3%	27,987 $439,000
Q2 2020 Aug 13, 2020	BUY	$13.04 - $23.23 $260,265 - $463,647	19,959 Added 157.18%	32,657 $572,000
Q4 2019 Feb 05, 2020	BUY	$15.24 - $25.09 $1,097 - $1,806	72 Added 0.57%	12,698 $319,000
Q3 2019 Oct 23, 2019	SELL	$14.91 - $25.01 $1,863 - $3,126	-125 Reduced 0.98%	12,626 $190,000
Q2 2019 Aug 14, 2019	BUY	$21.48 - $27.71 $63,903 - $82,437	2,975 Added 30.43%	12,751 $319,000
Q1 2019 May 01, 2019	BUY	$21.07 - $29.31 $27,412 - $38,132	1,301 Added 15.35%	9,776 $223,000
Q4 2018 Jan 31, 2019	BUY	$22.4 - $35.39 $189,840 - $299,930	8,475 New	8,475 $254,000

Others Institutions Holding CRNX

# of Institutions

241

Shares Held

79.5M

Call Options Held

23.3K

Put Options Held

44.3K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.9B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Crinetics Pharmaceuticals, Inc. Transaction History